1
|
Maddalon B, Cenzi C, Tonello M, Pizzolato E, Barina A, De Simoni O, Franzato B, Gruppo M, Mattara G, Tolin F, Moretto V, Nardi M, Zagonel V, Pilati P, Sommariva A. Clinical benefits of symptom resolution after palliative surgery in advanced cancer: A single-center experience. EUROPEAN JOURNAL OF SURGICAL ONCOLOGY 2024; 50:108368. [PMID: 38723448 DOI: 10.1016/j.ejso.2024.108368] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2024] [Revised: 04/13/2024] [Accepted: 04/23/2024] [Indexed: 05/26/2024]
Abstract
BACKGROUND Palliative surgery (PS) is defined as any surgical procedure aimed at improving quality of life or relieving symptoms caused by an advanced or metastatic cancer. The involvement of patients, caregivers, and other professional figures is crucial for obtaining optimal symptom relief and avoiding complications. This study aims to evaluate the short-term outcome and related factors in patients undergoing PS. PATIENTS AND METHODS A retrospective analysis was performed in consecutive patients who underwent palliative gastrointestinal surgery at our surgical unit during the period June 2018 to May 2023. Demographic, clinical, pathological and follow-up data were collected from a prospectively maintained department database. The main outcomes were complications, symptoms palliation, symptoms recurrence and return to systemic chemotherapy. Standard statistical analysis was performed. RESULTS During the study period, 127 patients underwent palliative surgery. The Clavien-Dindo 3-5 complication rate and mortality rate were 19.7 % and 6 %, respectively. The resolution of symptoms was achieved in 109 patients (89 %). Successful symptom palliation was significantly related to the possibility of returning to systemic chemotherapy (SC) (OR 9.30 95 % CI 0.1.83-47.18, p 0.007). The only factor related to survival in multivariate analysis was the return to systemic chemotherapy (HR 0.25 95 % CI 0.15-0.42 0.001). CONCLUSION PS in selected patients is effective for symptom resolution and improving overall survival, if the result is making anticancer therapy possible. Prospective data collection is in any case warranted in every institution performing PS for the purpose of monitoring appropriateness and quality of surgical care.
Collapse
Affiliation(s)
- Beatrice Maddalon
- Surgical Oncology of Digestive Tract, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy
| | - Carola Cenzi
- Clinical Research Unit, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy
| | - Marco Tonello
- Surgical Oncology of Digestive Tract, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy
| | - Elisa Pizzolato
- Surgical Oncology of Digestive Tract, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy
| | - Andrea Barina
- Surgical Oncology of Digestive Tract, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy
| | - Ottavia De Simoni
- Surgical Oncology of Digestive Tract, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy
| | - Boris Franzato
- Surgical Oncology of Digestive Tract, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy
| | - Mario Gruppo
- Surgical Oncology of Digestive Tract, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy
| | - Genny Mattara
- Surgical Oncology of Digestive Tract, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy
| | - Francesca Tolin
- Surgical Oncology of Digestive Tract, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy
| | - Valentina Moretto
- Nutritional Support Unit, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy
| | - Mariateresa Nardi
- Nutritional Support Unit, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy
| | - Vittorina Zagonel
- Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy
| | - Pierluigi Pilati
- Surgical Oncology of Digestive Tract, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy
| | - Antonio Sommariva
- Surgical Oncology of Digestive Tract, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
| |
Collapse
|
2
|
Muacevic A, Adler JR, Kopanakis N, Iavazzo C, Farfarelos C. Spiliotis-Farfarelos Maneuver for the Management of Small Bowel Obstruction and Frozen Pelvis in Patients With Peritoneal Metastasis. Cureus 2022; 14:e32518. [PMID: 36654562 PMCID: PMC9838686 DOI: 10.7759/cureus.32518] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/09/2022] [Indexed: 12/15/2022] Open
Abstract
The management of the advanced peritoneal disease is demanding especially in cases of extensive bowel infiltration and the obstruction of the gastrointestinal tract in different sites. Patients with bowel obstruction due to peritoneal carcinomatosis have an overall survival that ranges from three to eight months to four to five weeks based on the operability or not of the disease, respectively. The decision to operate should carefully consider the balance between the probability of symptomatic relief and the risk of severe perioperative complications and survival after surgery. The extent of the disease and postoperative malnutrition could further complicate patients' postoperative course. We aim to present an operative maneuver of bowel preparation and fixation in cases of extensive infiltration of the small bowel by peritoneal carcinomatosis (PC) in order to eliminate the risk of postoperative fistula formation or anastomotic leakage.
Collapse
|